We are live on ! Find out more
ATHE icon

Alterity Therapeutics
ATHE

14 hedge funds and large institutions have $494K invested in Alterity Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,360% more capital inflows, than outflows

Capital inflows: $52.7K | Capital outflows: $2.14K

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

8% more funds holding

Funds holding: 13 → 14 (+1)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$22.6K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$12.6K
3
UBS Group
UBS Group
Switzerland
+$9.8K
4
Citadel Advisors
Citadel Advisors
Florida
+$5.24K
5
Bank of America
Bank of America
North Carolina
+$679

Top Sellers

Rank Fund Capital Flow
1
Advisor Group
Advisor Group
Arizona
-$1.14K
2
Ferris Capital
Ferris Capital
Massachusetts
-$1K

ATHE Hedge Fund Activity: Q3 2017 in Review

14 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q3 2017, worth a combined $494K — up 37% from $361K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ATHE positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $22.6K. The largest seller was Advisor Group, cutting an estimated $1.14K.

  • 14 institutional investors held Alterity Therapeutics (ATHE) as of Q3 2017, up from 13 in Q2 2017.
  • Funds reported $494K of Alterity Therapeutics stock for Q3 2017, up 37% quarter-over-quarter.
  • 2 funds opened new Alterity Therapeutics positions in Q3 2017 and 1 closed out, a net change of +1 holder.
  • The largest Alterity Therapeutics buyer in Q3 2017 was Morgan Stanley, an estimated $22.6K added.
  • The largest Alterity Therapeutics seller in Q3 2017 was Advisor Group, an estimated $1.14K sold.

Based on aggregated 13F filings for Q3 2017.